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TWENTY-YEAR FOLLOW-UP OF A Pu/Am INHALATION CASE
C. Wernli and J. Eikenberg
Paul Scherrer Institute (PSI), 5232 Villigen, Switzerland
In 1983 a technician inhaled a mixture of Pu/Am aerosols in an accidental situation in the hotlab of Paul Scherrer Institute
(PSI). This case is of interest for long-term follow-up since the technician was relatively young (26 y) at the time of intake,
no chelating agent was used to alter retention and excretion and the inhaled activity was rather high ( 20 kBq of
alpha emitters). The results obtained from periodic lung counts, urinary and faecal excretions as well as from some bone
and liver measurements up to the year 2003 are presented. The measurements were mainly made at PSI but also at FZK
Karlsruhe, Germany, and PNNL Hanford, USA. The evaluation and dose estimation of this case was done by several
institutions, such as FZK, PNNL and NRPB in addition to PSI. Elements of the case were used in international biokinetic
model validation programs by EURADOS/EULEP and IAEA and the 241Am data are given as example in Annex E of
the ICRP ‘Guide for the Practical Application of the ICRP Human Respiratory Tract Model’. An overview is given on
the various results obtained by the different institutions using their models and methods for interpretation of the measured
data. While estimation of intake varies by more than an order of magnitude, final estimation of effective committed dose
varies only in the range of 0.5–1.5 Sv.
THE ACCIDENTAL SITUATION IN 1983
The former Swiss Federal Institute for Reactor
Research (EIR), now Paul Scherrer Institute (PSI)
operated a hot lab where research on nuclear fuel
has been performed for more than a decade. As a
consequence of the production of uranium/pluto-
nium carbide microsphere fuel elements some liquid
waste resulted. The volume of this liquid waste was
reduced periodically by evaporation in a special
apparatus within a glove box of the hot lab. On
one occasion an incident happened as described in
the original EIR report(1):
At 16:15 on 24 May 1983 a rapid chemical reac-
tion occurred in an apparatus in which a routine
waste sludge evaporation process was under way.
The waste was produced during fuel fabrication.
The resulting pressure wave ruptured a number of
parts at the glove box in which the equipment was
situated leading to an alpha contamination of that
and neighboring laboratories. The alarm system
activated by the fire alarm, the activity detectors
and manually by the operators functioned correctly.
A total of seven persons working in the imme-
diate surrounding of the place of the incident inhaled
a detectable amount of alpha emitting radionuclides.
For one person only the estimated committed dose
was above the legal limits. This refers to a young
man of 26 y at the time of the incident (M.D., born
in 1957). All data on measurements and analysis are
given for this person only.
The material dispersed at this incident was a mix-
ture of different waste products in various chemical
forms. Therefore, no detailed information could be
given on the chemical form and the particle size
distribution of the inhaled radioactive material. The
major component of the fuel material used at that
time was natural uranium and a plutonium mixture
with the badge name P-13. The typical ratio by
weight was 80% of uranium and 20% of P-13. The
activity of uranium was, therefore, several orders of
magnitude lower than for plutonium. The material
P-13 has a relative composition as given in Table 1.
This composition was assumed to be applicable for
the interpretation of the inhalation case.
Immediately after the incident the most affected
person (M.D.) was transferred to the EIR decontam-
ination facility. It turned out that his head and
neck were heavily contaminated. A nasal swab and
a bronchial slime probe were taken and after a first
decontamination a chest count was performed at
19:00 h of May 24. These first measurements gave
the following results: nasal swab, 5.5 kBq alpha
activity; bronchial slime, 1.4 kBq alpha activity;
chest count, 390 Bq 241Am, corresponding to 3.9 kBq
alpha activity (for P-13 material).
These results indicated the severity of the inhala-
tion case and the collection of urine and faeces and
a follow-up of chest counts was initiated. At that
time a decision had also to be taken on the applica-
tion of a chelating agent to enhance excretion.
Ampoules with Na- and Ca-DTPA were available
at the EIR decontamination facility for injection.
It was assumed that the inhaled Pu was in an insolu-
ble form and that diethylenetriaminepentacetate
(DTPA) would not significantly reduce committed
dose, even if it would enhance urinary excretion.
Therefore, it was decided not to apply the chelating
agents.Corresponding author: Christian.Wernli@psi.ch
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THE MEASUREMENTS PERFORMED
ON M.D.
In the 20-y follow-up of this case a total of >100
independent measurements were performed at five
different laboratories (see Table 2). These measure-
ments consisted of in vivomeasurements of the chest,
the lungs, the liver, the skeleton and the pulmonary
lymph nodes, as well as urinary and faecal analysis.
In 1992 a count of chromosomal aberrations in
peripheral lymphocytes was also initiated. The
results of these measurements are given in the
Annexure.
In vivo measurements
The measurement techniques and the calibration
methods for the in vivo measurements have changed
dramatically since 1983. The first measurements
were taken with phoswich NaI/CsI-detectors and
later on intrinsic germanium detector arrays were
used (planar n-type Ge-spectrometers). The three
laboratories involved in this type of measurements
(Lab 1, 2 and 3) did not directly compare their cali-
brations in a specific intercomparison exercise. How-
ever, all laboratories participated in international
intercomparison programs using the Livermore
phantom as a reference for chest and lungs. Some
effort was made to determine the uncertainty espe-
cially of the very early measurements performed at
Lab 1. Due to the fact that not all relevant informa-
tion was completely stored, it was not possible to
arrive at a standardised and uniform method for the
expression of uncertainty for all these measurements.
Therefore, it was decided to present the results with-
out indication of uncertainties.
Urine and faecal analysis
Prior to the chemical separation procedures to pre-
concentrate trace levels of Pu and Am, procedures
for sample dissolution are necessary. To destroy the
organic matter in urine, Lab 1 added 100 ml 14 Mol/l
HNO3 to 1 litre samples. After covering with watch
glass the solutions were then boiled for about 5 h
until a clear solution was obtained. The faecal sam-
ples were initially converted to dry ash in a high
temperature oven and the ash was then digested in a
glass beaker using a mixture of HNO3/H2SO4 under
boiling and back-flow via use of a condensation
tube. The clear solutions were then taken for radio-
chemical purification (next paragraph). For chemical
yield determination 243Am and 242Pu tracers were
added to the urine sample prior to oxidation and to
the faecal samples after it was converted to dry ash.
Initially Lab 1 applied a gross alpha method for
determination of transuranium isotopes via simulta-
neous adsorption of actinides on glass fibre materi-
als. This method was later replaced by extraction
chromatography methods using selective resins for
consecutive separation of Pu and Am isotopes. The
actinides of the urine samples are pre-concentrated
onto a highly selective extractant commercially avai-
lable as Actinide Resin (EiChrom SA, Darien, IL,
USA) simply by adding 200 mg resin to a 0.5 litre
sample and stirring for 1 h. The separation of the
resin containing the actinides from the bulk of the
solution is obtained via filtration on cellulose nitr-
ate membrane filters. Stripping of the reagent from
the inert support (polymeric substrate) is performed
using organic solvents such as isopropanol. After
decomposition on a heating plate the electrolytic
Table 1. Composition of the fuel material P-13 normalised
to total alpha activity.
Radionuclide Alpha activity Beta activity
238Pu 0.09
239Pu 0.55
240Pu 0.26
241Am 0.10
241Pu 7.50
Total 1.00 7.50
Table 2. Laboratories involved in measurements on the inhalation case of M.D.
Lab number Name of laboratory Type of measurements
Lab 1: PSI (former EIR), Villigen/Wu¨renlingen,
Switzerland
Chest counts were performed until 1991 with two
phoswich detectors installed in the PSI whole body
counter. Urine and faecal analysis
Lab 2: FZK (former KfK), Karlsruhe, Germany Chest counts were performed with phoswich detectors
and from 1991 lung, liver, bone and lymph node
measurements were made with Ge detectors.
Urine and faecal analysis
Lab 3: PNNL (former PNL), Richland, USA Lung, liver, skeleton and lymph node measurements
were made with Ge detectors
Lab 4: IT Corporation, Richland, USA Urine analysis
Lab 5: NRPB, Chilton, UK Counting of chromosome aberrations
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deposition is carried out in a NaHSO4/H2SO4 buffer
solution(2). Chemical separation of the ash samples is
carried out using an anion exchanger resin (Biorad
AG 1x 2) for isolation of Pu and a TRU-Spec, col-
umn (EiChrom) for subsequent extraction of Am.
After electrodeposition onto stainless steel plates
the Pu and Am fractions are analysed by means of
high resolution alpha spectrometry(3). For quality
control, Lab 1 continuously participated in interna-
tional intercomparison programs, e.g. organised by
the German Federal Department for Public Health
or the French ‘PROCORAD’ program.
The long-term retention of Am in the chest and
the excretion of Pu in urine and faeces are shown in
Figure 1. An interesting feature of this case is the
time-dependent variation in isotope composition.
This is due to two different effects. The inhaled
material contained a high initial activity ratio for
241Pu/241Am of 75. Since 241Pu has a relatively
short half-life of 14.35 y and the decay product is
241Am, there is a significant ingrowth of 241Am.
After 20 y and neglecting excretion the ingrowth of
241Am yielded 1.5 times the original amount of
the deposited 241Am.
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Figure 1. Results of in vivo (241Am) and excretion (238,239,240Pu and 241Am) measurements in three different laboratories
in the time period of 1983 until 2003.
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Figure 2. Ratio of americium to alpha emitting plutonium, in excretions of urine and faeces for a time period of 20 y
after the inhalation.
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In addition early excretions through urine and
faeces showed different behaviour. Lung clearance
in the early days resulted in a nuclide composition of
the faeces equal to the inhaled mix. Otherwise, early
urine samples showed a high concentration of 241Am
since americium in lungs has a higher excretion rate
via urine than plutonium. After several years the
excretion is not dominated any more from direct
deposition in the lungs and, therefore, the composi-
tion of the radionuclide in urine and faeces has
changed over time and has become similar as shown
in Figure 2.
Table 3. Evaluation of the inhalation case by different organisations.
Identification Type of study Model used
EIR, 1983 First EIR evaluation(4) ICRP 26, ICRP 30
EIR, 1984 Second EIR evaluation(5) ICRP 26, ICRP 30
NRPB, 1992 Chromosomal analysis on a blood sample(6)
FZK, 1995 Comparison of different models(7) FZK 241Am model(8), ICRP 26,
IRCP 60
PNL, 1995 Comparison of different models(9) ICRP 48, ICRP 66, ICRP 67,
Tancock 93(10)
NRPB, 1996 Evaluation of the inhalation case(11) ICRP 66, ICRP 67
IAEA, 1999 Intercomparison project(12)
with 25 participants
Various
FZK, 2000 Intercomparison project(13)
with 50 participants
ICRP 30, ICRP 54, ICRP 66, ICRP 67
FZK, 2002 Optimisation of ICRP model(14) ICRP 67 modified
ICRP, 2002 Application of the ICRP Human Respiratory
Tract Model(15) with 241Am data
ICRP 30, ICRP 66, ICRP 67
IDEAS, 2005 Intercomparison project(16) with 35 participants ICRP 66, ICRP 67
Table 4. Results of the different evaluations.
Identification Estimated committed dose (Sv)
238Pu 239Puþ 240Pu 241Am Total alpha 241Pu Total
EIR, 1983 0.1–1.2
EIR, 1984 1.3 0.2 1.5
FZK, 1995
ICRP 26 0.74 0.13 0.87 0.23 1.10
IRCP 60 0.55 0.09 0.64 0.15 0.79
PNL, 1995 0.46
NRPB, 1996 0.08 0.72 0.09 0.89 0.11 1.0
IAEA, 1999 GM: 0.11 GM: 0.63 GM: 0.14
AM: 0.13 AM: 0.88 AM: 0.21
(0.04–0.3) (0.2–1.9) (0.04–0.8)
FZK, 2000
ICRP 30 þ GM: 0.32
ICRP 54 AM: 0.45
(0.07–1.4)
ICRP 66 þ GM: 0.19
ICRP 67 AM: 0.24
(0.04–0.6)
FZK, 2002 0.044 0.28þ 0.13 0.13 0.58 0.058 0.64
ICRP, 2002 0.06
IDEAS, 2005 239Pu only
GM: 0.14 GM: 0.053
AM: 0.16 AM: 0.070
(0.001–1.1) (0.00006–0.3)
NRPB, 1992 Average dose to lymphocytes: 0.5–2
GM: Geometric mean. AM: Arithmetic mean of all results of the intercomparison, minimum and maximum in parentheses
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THE INTERPRETATION OF
THE MEASUREMENTS
This inhalation case has been analysed by quite a
number of institutions. The early evaluation had to
be done at PSI for reporting to the competent
authorities(4,5). Later on the scientific interest in the
case came up, especially since retention and excre-
tion were not influenced by chelating agents. The
first international study of the case was performed
under a CEC contract in the Third Nuclear Fission
Framework Programme (1992–1995). In the follow-
ing years the case was subject of numerous actions
as shown in Table 3.
Intake was estimated by different institutions
using various models. These estimates varied over
more than an order of magnitude. Based on the
ICRP Publications 66 and 67 the most probable
values are 30–40 kBq of alpha emitting Pu isotopes
and 241Am, and 200–300 kBq 241Pu. The wide varia-
tion of the estimates has shown, that intake is only
then a meaningful quantity to characterise the extent
of an inhalation case if the model used for intake
estimation is given and the same model is used to
determine committed dose.
The estimation of committed dose has shown a
wide variation among different institutions. The rea-
son for this seems to be the variability of the local
application of procedures and methods of dose
estimation and not primarily the metabolic and dosi-
metric models used as such. In the 20 y observation
period of this case the recommended internal
dosimetry models have changed mainly from ICRP
26/ICRP 30 to ICRP 66/ICRP 67, not to mention the
many supporting documents and the various models
proposed by individual scientists. Overall, the inter-
pretation and the dose estimation of the case have
not changed dramatically with the application of
the new models. It is assumed that the effective
committed dose (E50) is in the order of 1 Sv with
an uncertainty of <0.5 Sv.
CONCLUSIONS AND OUTLOOK
The 1983 Pu inhalation case has become an impor-
tant issue for model validation studies and training
events in internal dosimetry. It is planned to con-
tinue the measurements as long as the subject is
willing to participate. Following this overview of
the history of the inhalation case a scientific paper
on the application of the actual ICRP models will be
prepared in collaboration with colleagues from other
institutions.
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ANNEX: RESULTS OF ACTIVITY
MEASUREMENTS
Table A2. Activity of 241Am in lung, liver, lymph and bone.
Laboratory Organ Time after
intake (d)
Activity of
241Am (Bq)
Lab 3 Lung 3724 120
Lab 2 Lung 3828 120
Lab 2 Lung 5110 133
Lab 3 Liver 3724 57
Lab 2 Liver 3828 24
Lab 2 Liver 5110 17
Lab 3 Lymph 3724 26
Lab 2 Lymph 3828 72
Lab 2 Lymph 5110 76
Lab 3 Bone 3724 69
Lab 2 Bone 3828 65
Lab 2 Bone 5110 95
Table A1. Chest measurements of 241Am.
Laboratory Time after
intake (d)
Activity of
241Am (Bq)
Lab 1 0.1 390
Lab 1 1 310
Lab 1 3 230
Lab 1 6 240
Lab 1 15 230
Lab 1 34 230
Lab 2 38 260
Lab 1 44 230
Lab 1 160 220
Lab 2 164 230
Lab 1 357 220
Lab 1 1077 240
Lab 1 2925 180
The 241 Am detected in the chest measurements at later
times results from 241Am located in the lung, the pulmonary
lymph nodes and the ribs of the subject.
Table A3. Continued
Lab Time after
intake (d)
239Puþ 240Pu
[mBq/d]
241Amþ238Pu
[mBq/d]
Lab 1 30 4 6
Lab 1 31 4 6
Lab 1 37 6 6
Lab 1 180 3 4
Lab 1 43 4 5
Lab 1 179 5 4
Lab 1 180 3 4
Lab 1 182 4 6
Lab 1 183 3 4
Lab 1 364 5 4
Lab 1 365 2 3
Lab 1 366 2 2
Lab 1 369 4 5
Lab 1 370 5 7
Lab 1 371 4 4
Lab 1 605 3 3
Lab 1 606 4 5
Lab 1 607 2 2
Lab 1 1074 2 2
Lab 1 1075 4 3
Lab 1 1076 3 3
Lab 1 1077 6 3
Lab 1 1921 6 6
Lab 1 1922 5 5
Lab 1 1923 7 4
Lab 1 2089 7 5
Lab 1 2090 5 4
Lab 1 2091 7 3
Lab 1 3902 3 3
Lab 1 5076 9 4
Lab 2 6043 11 6
Lab 2 6044 10 3
Lab 2 6045 16 6
Lab 1 6859 10 6
Lab 1 6860 10 4
Lab 1 6870 9 4
238,239,240Pu
[mBq/d]
241Am
[mBq/d]
Lab 1 2092 2
Lab 1 2095 4
Lab 2 2525 4 <1.5
Lab 2 2526 6 5
Lab 2 2527 7 3
Lab 2 2921 5 3
Lab 2 2922 4 2
Lab 2 2923 <1.5 <1.5
Lab 3 3723 10
Lab 3 3725 9
Lab 2 6043 13 5
Lab 2 6044 10 2
Lab 2 6045 17 5
Lab 1 6859 10 5
Lab 1 6860 10 3
Lab 1 6861 9 3
Table A3. Excretion in urine.
Lab Time after
intake (d)
239Puþ 240Pu
[mBq/d]
241Amþ238Pu
[mBq/d]
Lab 1 1 11 110
Lab 1 2 41 100
Lab 1 13 6 17
Lab 1 14 4 15
Lab 1 21 4 11
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Table A4. Excretion in feces.
Lab Time after
intake (d)
239Puþ 240Pu
[mBq/d]
241Amþ 238Pu
[mBq/d]
Lab 1 1 5 200 000 1 500 000
Lab 1 2 3 000 000 740 000
Lab 1 3 440 000 74 000
Lab 1 13 670 160
Lab 1 20 960 190
Lab 1 21 480 110
Lab 1 30 670 120
Lab 1 37 250 78
Lab 1 43 260 74
Lab 1 44 160 44
Lab 1 179 590 120
Lab 1 180 470 100
Lab 1 182 310 93
Lab 1 183 310 63
Lab 1 365 340 81
Lab 1 366 150 26
Lab 1 369 440 110
Lab 1 370 180 37
Lab 1 371 180 41
Lab 1 605 300 85
Lab 1 606 300 80
Lab 1 607 170 59
Lab 2 6043 12 5
Lab 2 6044 13 5
Lab 2 6045 8 2
Lab 1 6859 4 1
Lab 1 6860 14 3
Lab 1 6861 7 3
238,239,240Pu
[mBq/d]
241Am
[mBq/d]
Lab 1 1074 70 18
Lab 1 1075 120 30
Lab 1 1076 65 17
Lab 1 1077 25 7
Lab 1 1921 90 13
Lab 1 1922 190 46
Lab 1 1923 100 15
Lab 2 2525 47 17
Lab 2 2526 17 5
Lab 2 2527 38 13
Lab 2 2921 5 <1.5
Lab 2 2922 13 6
Lab 2 2923 3 <1.5
Lab 3 3723 15
Lab 3 3725 11
Lab 2 6043 13 4
Lab 2 6044 14 4
Lab 2 6045 9 2
Lab 1 6859 4 1
Lab 1 6860 14 2
Lab 1 6861 8 2
Table A5. Ratio of americium to total a-emitting plutonium
in feces and urine.
Days Ratio 241Am/
(238Puþ239Puþ240Pu)
Feces Urine
1 0.13 8.9
2 0.11 2.1
3 0.08
13 0.11 2.96
21 0.09 2.58
30 0.08 1.26
37 0.13 0.80
44 0.12 1.16
181 0.10 1.02
369 0.10 0.93
606 0.13 0.96
1076 0.26 0.56
1922 0.19 0.62
2526 0.35 0.63
2922 0.43 0.51
6044 0.26 0.26
6860 0.22 0.38
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